H.R. 8160

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8160 Introduced in House (IH)]

<DOC>

119th CONGRESS
2d Session
H. R. 8160

To expand research, improve awareness, and increase access to treatment 
for individuals affected by Premenstrual Dysphoric Disorder, and for 
other purposes.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

March 30, 2026

Ms. Ansari (for herself, Mrs. Beatty, Mr. Bell, Ms. Brownley, Mr. 
Carter of Louisiana, Ms. Clarke of New York, Mr. Conaway, Mr. Goldman 
of New York, Mrs. Grijalva, Mr. Jackson of Illinois, Mr. Johnson of 
Georgia, Mr. Kennedy of New York, Mr. Krishnamoorthi, Mr. McGarvey, Ms. 
Norton, Ms. Pressley, Ms. Ross, Mr. Thanedar, Ms. Tlaib, Mr. Tonko, 
Mrs. Trahan, Ms. Velazquez, Ms. Williams of Georgia, and Ms. Wilson of 
Florida) introduced the following bill; which was referred to the 
Committee on Energy and Commerce

_______________________________________________________________________

A BILL

To expand research, improve awareness, and increase access to treatment 
for individuals affected by Premenstrual Dysphoric Disorder, and for 
other purposes.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Premenstrual Dysphoric Disorder 
Awareness and Research Act of 2026''.

SEC. 2. FINDINGS.

Congress finds the following:
(1) Premenstrual Dysphoric Disorder (referred to in this 
section as ``PMDD'') is a severe, chronic, and often disabling 
medical condition affecting an estimated 5 to 8 percent of 
women and people assigned female at birth of reproductive age.
(2) PMDD is characterized by extreme mood shifts, 
irritability, depression, anger, hopelessness, tension, 
anxiety, and physical symptoms, such as difficulty 
concentrating, change in appetite, decreased energy, over or 
under sleeping, or joint and muscle aches, in the luteal phase 
of the menstrual cycle, significantly impairing work, 
education, and daily life.
(3) Despite its prevalence and debilitating impact, PMDD 
remains under-diagnosed, under-researched, and stigmatized.
(4) Early detection, effective treatment, and increased 
public and provider awareness are essential to improving 
quality of life for individuals living with PMDD.

SEC. 3. RESEARCH WITH RESPECT TO PREMENSTRUAL DYSPHORIC DISORDER 
(PMDD).

(a) In General.--The Secretary of Health and Human Services (in 
this section referred to as the ``Secretary''), acting through the 
Director of the National Institutes of Health, shall--
(1) expand and intensify research on Premenstrual Dysphoric 
Disorder (referred to in this section as ``PMDD''), including 
the causes, risk factors, diagnosis, and treatment of PMDD;
(2) support clinical trials to develop improved treatment 
options for PMDD; and
(3) ensure adequate representation of diverse racial, 
ethnic, and socioeconomic populations in PMDD-related research.
(b) Surveillance and Data Collection.--The Secretary shall collect 
and publish data on--
(1) the prevalence and incidence of PMDD across 
populations;
(2) the economic and workforce impact of PMDD; and
(3) barriers to diagnosis and treatment of PMDD.
(c) Authorization of Appropriations.--To carry out this section 
there are authorized to be appropriated such sums as is necessary for 
each of fiscal years 2027 through 2031.

SEC. 4. EDUCATION AND DISSEMINATION OF INFORMATION WITH RESPECT TO 
PREMENSTRUAL DYSPHORIC DISORDER (PMDD).

(a) In General.--The Secretary shall carry out a public health 
awareness campaign that is designed to--
(1) raise patient and health care provider awareness of 
PMDD symptoms and treatment options;
(2) reduce stigma associated with menstrual health 
conditions; and
(3) encourage individuals to seek timely medical care.
(b) Provider Education.--The Secretary, acting through the 
Administrator of the Health Resources and Services Administration, 
shall develop, and disseminate, continuing medical education materials 
to ensure that health care providers have sufficient knowledge--
(1) to accurately diagnose PMDD;
(2) to distinguish PMDD from other mental health and 
gynecological conditions; and
(3) to provide evidence-based care.
(c) Coordination.--In carrying out this section, the Secretary 
shall coordinate with existing awareness, education, and outreach 
programs and activities of the Department of Health and Human Services.
(d) Authorization of Appropriations.--To carry out this section 
there are authorized to be appropriated such sums as is necessary for 
each of fiscal years 2026 through 2030.

SEC. 5. GRANTS TO TRAIN HEALTH PROFESSIONALS WITH RESPECT TO PMDD.

(b) In General.--The Secretary shall award grants to eligible 
entities for the purpose described in subsection (b).
(c) Use of Funds.--A grant awarded under this subsection shall be 
used to develop, establish, or expand training programs (including 
accredited residency programs, fellowships, or other related clinical 
training) for physicians, registered nurses, nurse practitioners, 
physician assistants, pharmacists, other health care providers, and 
students and trainees to improve care, treatment, or management 
services for PMDD.
(d) Eligibility.--To be eligible to receive a grant under this 
subsection, an entity shall--
(1) be--
(A) an accredited school of medicine or osteopathic 
medicine;
(B) an accredited nursing school;
(C) an accredited school of pharmacy;
(D) an accredited public or nonprofit private 
hospital;
(E) an accredited medical residency program;
(F) an accredited nurse practitioner residency 
program; or
(G) a related training program for clinicians, 
allied health professionals, or social workers that 
interface with affected populations, which may include 
hospitals and research institutions, as determined by 
the Secretary; and
(2) submit an application to the Secretary at such time, in 
such manner, and containing such information as the Secretary 
may require.
(e) Training Opportunities.--In carrying out this section, the 
Secretary shall expand outreach activities to support and expand 
training programs, fellowships, and other opportunities for students, 
faculty, and trainees (including continuing medical education) or 
establish new training opportunities to address barriers to access to--
(1) primary and specialty care services to support mid-life 
women's health; and
(2) early detection, diagnosis, treatment, and care 
services for perimenopause, menopausal symptoms, and related 
chronic conditions.
(f) Authorization of Appropriations.--To carry out this section 
there are authorized to be appropriated such sums as is necessary for 
each of fiscal years 2027 through 2031.

SEC. 6. REPORT ON IMPACTS ON PMDD RESEARCH AND TREATMENT.

(a) Report.--Not later than 2 years after the date of the enactment 
of this Act, the Secretary shall submit to Congress a report on 
progress made in--
(1) expanding PMDD research;
(2) improving awareness of, and education on, PMDD; and
(3) increasing access to diagnosis of, and treatment for, 
PMDD.
(b) Authorization of Appropriations.--To carry out this section 
there are authorized to be appropriated such sums as is necessary for 
each of fiscal years 2027 through 2031.
<all>